Cargando…
Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report
BACKGROUND: In this era of molecular targeting therapy when various systematic treatments can be selected, prognostic biomarkers are required for the purpose of risk-directed therapy selection. Numerous reports of various malignancies have revealed that 18-Fluoro-2-deoxy-D-glucose ((18)F-FDG) accumu...
Autores principales: | Namura, Kazuhiro, Minamimoto, Ryogo, Yao, Masahiro, Makiyama, Kazuhide, Murakami, Takayuki, Sano, Futoshi, Hayashi, Narihiko, Tateishi, Ukihide, Ishigaki, Hanako, Kishida, Takeshi, Miura, Takeshi, Kobayashi, Kazuki, Noguchi, Sumio, Inoue, Tomio, Kubota, Yoshinobu, Nakaigawa, Noboru |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016292/ https://www.ncbi.nlm.nih.gov/pubmed/21129184 http://dx.doi.org/10.1186/1471-2407-10-667 |
Ejemplares similares
-
FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma
por: Nakaigawa, Noboru, et al.
Publicado: (2016) -
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
por: Kakizoe, Manabu, et al.
Publicado: (2014) -
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
por: Ueno, Daiki, et al.
Publicado: (2012) -
The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy
por: Nakaigawa, Noboru, et al.
Publicado: (2017) -
Early assessment with (18)F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
por: Tabei, Tadashi, et al.
Publicado: (2019)